SCHEMBL2939909

SCHEMBL2939909

Cc1onc(-c2c(Cl)cccc2Cl)c1C(=O)N1CCC2(CC1)NC(Cc1ccccc1)C(=O)N2CC(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.52
MEN1 O00255 2/20 0.51
TDP1 Q9NUW8 1/20 0.51
CYP2C9 P11712 2/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C19 P33261 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
KDM4E B2RXH2 1/20 0.48
POLB P06746 1/20 0.48
TSHR P16473 2/20 0.47
LMNA P02545 4/20 0.45
ALDH1A1 P00352 3/20 0.45
HTT P42858 2/20 0.45
USP2 O75604 1/20 0.44
EPAS1 Q99814 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
GAA P10253 2/20 0.44
ATM Q13315 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1803216 0.96 KMT2A (0.55) KMT2AMEN1TDP1CYP2C9CYP3A4
SCHEMBL1802313 0.86 KMT2A (0.51) KMT2AMEN1TDP1CYP2C9CYP3A4
SCHEMBL1802086 0.82 KMT2A (0.53) KMT2AMEN1TDP1KDM4ETSHR
SCHEMBL1800789 0.78 KMT2A (0.58) KMT2AMEN1TDP1CYP2C9CYP3A4
SCHEMBL2938492 0.78 CHRNA4 (0.41) CYP2C9CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL2942653 0.77 HPGD (0.42) KMT2AMEN1NPSR1POLBTSHR
SCHEMBL2938363 0.77 CYP2C9 (0.45) CYP2C9CYP2C19KDM4EPOLBLMNA
SCHEMBL1802265 0.77 KMT2A (0.55) KMT2AMEN1TDP1CYP2C9CYP3A4
SCHEMBL2943001 0.76 MEN1 (0.39) KMT2AMEN1CYP3A4CYP2D6CYP2C19
SCHEMBL2932813 0.75 MEN1 (0.43) KMT2AMEN1KDM4ETSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1730147-B1 SUBSTITUTED 1,4,8-TRIAZASPIRO[4,5]DECAN-2-ON COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY GRUENENTHAL GMBH (DE) 2010-02-03 EP claimed
US-20070015784-A1 Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2007-01-18 US claimed
US-20070015784-A1 Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015784-A1 Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds SI, SSTR4, SLC10A2 KMT2A 4267/4885MEN1 1474/4885TDP1 2141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.